Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2005.051417v1, 2005; 10.1373/clinchem.2005.051417
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplements
Right arrow All Versions of this Article:
clinchem.2005.051417v1
51/9/1637    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banks, R. E.
Right arrow Articles by Selby, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banks, R. E.
Right arrow Articles by Selby, P. J.

Received on March 21, 2005
Accepted on June 1, 2005

Proteomics and Protein Markers

Influences of Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry

Rosamonde E. Banks 1, Anthea J. Stanley 1, David A. Cairns 1, Jennifer H. Barrett 1, Paul Clarke 1, Douglas Thompson 2, Peter J. Selby 1

1 Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, UK
2 Department of Clinical Biochemistry and Immunology, Leeds General Infirmary, Leeds, UK

Background: Profiling approaches in proteomics, such as surface-enhanced laser desorption/ionization (SELDI) mass spectrometry, are used in disease marker discovery. The aim of this study was to investigate the potential influence of selected preanalytical factors on the results obtained.

Methods: Plasma samples anticoagulated with EDTA, citrate, or heparin, and serum samples from healthy volunteers were profiled by SELDI on CM10, immobilized metal affinity capture (IMAC) array with copper surface, and H50 chip surfaces. With linear mixed-effects models, we examined the influence of elapsed time between venipuncture and sample separation (immediate to 24 h) and the type of serum tube used (Greiner Vacuette activator, gel serum separator, or plain tubes). We analyzed purified platelets, as well as platelet-poor and platelet-rich plasma samples treated with calcium and/or thrombin to determine the platelet contribution, directly or via the clotting process, to the profiles generated. We then used cluster analysis to identify samples with similar peak profiles.

Results: Different plasma types and sera could be distinguished on the basis of cluster analyses of their spectral profiles. Elapsed time between venipuncture and separation of plasma and serum from blood samples altered the profiles obtained, particularly for serum samples and particularly on IMAC chips. The type of serum collection tube also affected the profiles because of differences in clotting time. In vitro manipulation of platelets revealed that specific peaks in IMAC profiles of serum appeared to be derived directly from platelets. Several other peaks, including some of those exhibiting time-dependent changes, arose during the clotting process.

Conclusion: Preanalytical variables, such as sample handling, can markedly influence results.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Cancer Res.Home page
G. M. Fiedler, A. B. Leichtle, J. Kase, S. Baumann, U. Ceglarek, K. Felix, T. Conrad, H. Witzigmann, A. Weimann, C. Schutte, et al.
Serum Peptidome Profiling Revealed Platelet Factor 4 as a Potential Discriminating Peptide Associated with Pancreatic Cancer
Clin. Cancer Res., June 1, 2009; 15(11): 3812 - 3819.
[Abstract] [Full Text] [PDF]


Home page
Cancer Genomics ProteomicsHome page
B. A. ZEIDAN, R. I. CUTRESS, N. MURRAY, G. R. COULTON, C. HASTIE, G. PACKHAM, and P. A. TOWNSEND
Proteomic Analysis of Archival Breast Cancer Serum
Cancer Genomics Proteomics, May 1, 2009; 6(3): 141 - 147.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. S. Tworoger, D. Spentzos, F. T. Grall, T. A. Liebermann, and S. E. Hankinson
Reproducibility of Proteomic Profiles Over 3 Years in Postmenopausal Women Not Taking Postmenopausal Hormones
Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1480 - 1485.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. Mannello
Serum or Plasma Samples?: The "Cinderella" Role of Blood Collection Procedures Preanalytical Methodological Issues Influence the Release and Activity of Circulating Matrix Metalloproteinases and Their Tissue Inhibitors, Hampering Diagnostic Trueness and Leading to Misinterpretation
Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 611 - 614.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
D. McLerran, W. E. Grizzle, Z. Feng, W. L. Bigbee, L. L. Banez, L. H. Cazares, D. W. Chan, J. Diaz, E. Izbicka, J. Kagan, et al.
Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias
Clin. Chem., January 1, 2008; 54(1): 44 - 52.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
E. P. Diamandis
Oncopeptidomics: A Useful Approach for Cancer Diagnosis?
Clin. Chem., June 1, 2007; 53(6): 1004 - 1006.
[Full Text] [PDF]


Home page
aacredbookHome page
E. P. Diamandis
Is Early Detection of Cancer with Serum Biomarkers or Proteomic Profiling Feasible?
Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 129 - 132.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
J. F. Timms, E. Arslan-Low, A. Gentry-Maharaj, Z. Luo, D. T'Jampens, V. N. Podust, J. Ford, E. T. Fung, A. Gammerman, I. Jacobs, et al.
Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles
Clin. Chem., April 1, 2007; 53(4): 645 - 656.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
W. C.S. Cho, T. T.C. Yip, R. K.C. Ngan, T.-T. Yip, V. N. Podust, C. Yip, H. H.Y. Yiu, V. Yip, W.-W. Cheng, V. W.S. Ma, et al.
ProteinChip Array Profiling for Identification of Disease- and Chemotherapy-Associated Biomarkers of Nasopharyngeal Carcinoma
Clin. Chem., February 1, 2007; 53(2): 241 - 250.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. V. Gnatenko, P. L. Perrotta, and W. F. Bahou
Proteomic approaches to dissect platelet function: half the story
Blood, December 15, 2006; 108(13): 3983 - 3991.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
R. Pilny, P. Bouchal, S. Borilova, P. Ceskova, J. Zaloudik, R. Vyzula, B. Vojtesek, and D. Valik
Surface-Enhanced Laser Desorption Ionization/Time-of-Flight Mass Spectrometry Reveals Significant Artifacts in Serum Obtained from Clot Activator-Containing Collection Devices.
Clin. Chem., November 1, 2006; 52(11): 2115 - 2116.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
G. L. Hortin
The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome
Clin. Chem., July 1, 2006; 52(7): 1223 - 1237.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. P. Diamandis
Serum Proteomic Profiling by Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry for Cancer Diagnosis: Next Steps
Cancer Res., June 1, 2006; 66(11): 5540 - 5541.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
E. P. Diamandis
Validation of breast cancer biomarkers identified by mass spectrometry.
Clin. Chem., April 1, 2006; 52(4): 771 - 772.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
O. J. Semmes
The "omics" Haystack: Defining Sources of Sample Bias in Expression Profiling
Clin. Chem., September 1, 2005; 51(9): 1571 - 1572.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the American Association for Clinical Chemistry.